

Personal data

Andreas Munk Petersen

Born November 30, 1963, Danish citizen

- Numerous self-initiated randomized and placebo-controlled studies on effect of Fecal Microbiota Transplant and/or probiotics in various diseases and participation in several clinical trials regarding new treatments for IBD under GCP rules in a referral hospital for all IBD patients (above 3000) from an area of 500000 inhabitants in the Southern part of Denmark's Capital Region.
- Clinical Associate Professor, University of Copenhagen, 01-09-14 to 31-07-18
- Clinical Research Associate Professor, University of Copenhagen since 01-08-2018 to 31-01-2024
- Clinical Professor, University of Copenhagen, 01-02-24
- Vast teaching experience including planning of symposia in Gut Microbiota and recurrent *C. difficile* infection.
- Supervisor of PhD students (14 in all, 7 as main supervisor), current (4) and previous (10)
- PhD-evaluations (4)
- Supervision of Master- (7) and Bachelor- (10) theses.
- Teaching experience in advanced medical courses for specialist trainees, at Herlev Hospital and Statens Serum Institut, Copenhagen
- Scientific reviewer for international journals
- Editorial Board Member, Gut Microbes (IF 9.4)
- Co-author "Akutte medicinske tilstande", FADL's forlag, 2009, 2011, 2013, 2015, 2016, 2019, 2021.
- Co-author "100 myter om fordøjelse og kost", FADL's forlag 2017
- Co-author "100 myter om alt mellem himmel og jord", FADL's forlag 2019
- Chairman for an Action Group against Clostridium difficile (under Task Force Hospital Acquired Infections in the Capital Region of Denmark)
- Completed the course "Ilederuddannelsen for Amager og Hvidovre Hospital" 2010, Udviklings- og uddannelsesafdelingen, Hvidovre Hospital
- Completed the course "Ledelse af forskning" Hold nr. 01-2014, Region Hovedstaden
- Currently 93 publications in peer-reviewed journals
- Interviewed as expert in gastroenterology and microbiome research for multiple articles and programs in most major Danish media, radio, TV and newspapers, including podcasts.

Positions and Honors

Education

1982 Student (high school), Frederiksværk Amtsgymnasium, Denmark

1990 **MD**, University of Copenhagen, Denmark

2000 **PhD degree**, University of Copenhagen, Denmark, 14th of September,

2005 Specialist in medical gastroenterology

2006 Specialist in internal medicine

2022 **Doctoral degree, DMSc**, University of Copenhagen, Denmark, 10th of November,

Career/Employments in

1990-93 Internship, Aalborg Hospital, Hvidovre Hospital and Køge Hospital

1994-96 Fellowship, Herlev Hospital.

1996-2000 Research scientist, PhD student, Statens Serum Institut

2000-06 Specialist training, Copenhagen University Hospital Herlev Hospital and Gentofte Hospital

2006-07 Consultant in Internal Medicine, Gentofte Hospital

2007- Consultant in Gastroenterology, Copenhagen University Hospital Hvidovre, and since December 2010 part time research scientist Statens Serum Institut (2010-2014) and Department of Clinical Microbiology, Copenhagen University Hospital Hvidovre (since 2014)

Short term fellowships

1998 (3 months) Stanford University, Department of Microbiology and Immunology, CA., USA

Selected Peer-reviewed Publications

10 most relevant Peer-reviewed publications

10. Fecal microbiota transplantation for the treatment of irritable bowel syndrome: A systematic review and meta-analysis. Halkjær SI, Lo B, Cold F, Christensen AH, Holster S, König J, Brummer RJ, Aroniadis OC, Lahtinen P, Holvoet T, Gluud LL, Petersen AM. Accepted for publication in WJG May 2023.
9. Synbiotic Intervention with Lactobacilli, Bifidobacteria, and Inulin in Healthy Volunteers Increases the Abundance of Bifidobacteria but Does Not Alter Microbial Diversity. Rubin IMC, Møllerup S, Broholm C, Baker A, Holm MKA, Pedersen MS, Pinholt M, Westh H, Petersen AM. *Appl Environ Microbiol*. 2022 Oct 11;88(19):e0108722.
8. No Effect of Lactobacillus rhamnosus GG on Eradication of Colonization by Vancomycin-Resistant Enterococcus faecium or Microbiome Diversity in Hospitalized Adult Patients. Rubin IMC, Møllerup S, Broholm C, Knudsen SB, Baker A, Helms M, Holm MKA, Kallemose T, Westh H, Dahl Knudsen J, Pinholt M, Petersen AM. *Microbiol Spectr*. 2022 Apr 27:e0234821.
7. Randomised clinical trial: A 12-strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent *Clostridioides difficile* infections. Rode A, Mahtab C, Rindom Krogsgaard L, Høno KK, Svendsen AT, Ribberholt I, Helms M, Engberg J, Schønning K, Tvede M, Andersen CØ, Jensen US, Petersen AM, Bytzer P. *Alimentary Pharmacology & Therapeutics* 2021, accepted for publication Feb 2021.
6. Ulcerative Colitis-associated *E. coli* pathobionts potentiate colitis in susceptible hosts. Yang H, Mirsepasi-Lauridsen HC, Struve C, Allaire JM, Sivignon A, Vogl W, Bosman ES, Ma C, Fotovati A, Reid GS, Li X, Petersen AM, Gouin SG, Barnich N, Jacobson K, Yu HB, Krogfelt KA, Vallance BA. *Gut Microbes*. 2020 Nov 9;12(1):1847976.
5. Multistrain Probiotic Increases the Gut Microbiota Diversity in Obese Pregnant Women: Results from a Randomized, Double-Blind Placebo-Controlled Study. Halkjær SI, de Knecht VE, Lo B, Nilas L, Cortes D, Pedersen AE, Mirsepasi-Lauridsen HC, Andersen LO, Nielsen HV, Stensvold CR, Johannesen TB, Kallemose T, Krogfelt KA, Petersen AM. *Curr Dev Nutr*. 2020 May 27;4(7):nzaa095. doi: 10.1093/cdn/nzaa095. eCollection 2020 Jul.
4. Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebo-controlled study. Halkjær SI, Christensen AH, Lo BZS, Browne PD, Günther S, Hansen LH, Petersen AM. *Gut*. 2018 Dec;67(12):2107-2115. doi: 10.1136/gutjnl-2018-316434. Epub 2018 Jul 6.
3. Use of prophylactic *Saccharomyces boulardii* to prevent *Clostridium difficile* infection in hospitalized patients: a controlled prospective intervention study. Carstensen JW, Chehri M, Schønning K, Rasmussen SC, Anhøj J, Godtfredsen NS, Andersen CØ, Petersen AM. *Eur J Clin Microbiol Infect Dis*. 2018 Aug;37(8):1431-1439. doi: 10.1007/s10096-018-3267-x. Epub 2018 May 3.
2. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease. Kantsø B, Halkjær SI, Thomsen OØ, Belard E, Gottschalk IB, Jørgensen CS, Krogfelt KA, Slotved HC, Ingels H, Petersen AM. *Vaccine*. 2015 Oct 5;33(41):5464-9. doi: 10.1016/j.vaccine.2015.08.011. Epub 2015 Aug 12.
1. Ciprofloxacin and probiotic *Escherichia coli* Nissle add-on treatment in active ulcerative colitis: a double-blind randomized placebo controlled clinical trial. Petersen AM, Mirsepasi H, Halkjær SI, Mortensen EM, Nordgaard-Lassen I, Krogfelt KA. *J Crohns Colitis*. 2014 Nov;8(11):1498-505. doi: 10.1016/j.crohns.2014.06.001. Epub 2014 Jun 25.

Research Support

- As PI or co-PI over the years received external funding + 30.000.000,- DKK in all.
- External funding received as PI or co-PI 2020-2023 + 20.000.000,- DKK in all. obtained from among others:
 - Regionernes medicin og behandlingspulje (governmental funds). As PI received 1.900.000 DKK for randomized placebo-controlled trial studying the effect of Fecal Microbiota Transplant on eradication of multi drug resistant organisms in intestinal carriers
 - Christian Hansen A/S (multinational Danish company). As PI received +4.000.000 DKK for placebo-controlled randomized studies of probiotics in Crohn's disease, Irritable Bowel Syndrome and recurrent Urinary Tract Infections
 - ParaTech A/S (Danish company), As PI received 3.000.000. DKK for a randomized placebo-controlled trial of Trichuris Suis Ova for patients with moderate ulcerative colitis
 - Danmarks Frie Forskningsfond (governmental funds, As PI received further 2.100.000 DKK for research in effect of Fecal Microbiota Transplant on eradication of multi drug resistant organisms in intestinal carriers
 - Freya Bioscience (Danish company), as co-PI received 8.000.000 DKK for a randomized placebo-controlled trial of vaginal microbiota transplantation in women with vaginal dysbiosis.
 - Colitis-Crohn foreningen (Danish Colitis Crohn patients), Copenhagen University and the Capital Regions research fund. Up to 1.000.000,-DKK for parts of all the mentioned projects.